Esafosfina belongs to the group of electrolyte solution drugs that regulate water-electrolyte balance and acid-base equilibrium, containing key ingredients such as sodium salts of fructose-1,6-diphosphate. Esafosfina 5g/50ml is indicated for patients with myocardial infarction, shock treatment, and severe ischemia in the lower limbs.
1. Effects of Esafosfina
Esafosfina contains sodium salts of fructose-1,6-diphosphate (FdP) at a concentration of 5g, equivalent to 3.75g of fructose-1,6-diphosphoric acid. It is formulated as a lyophilized powder for intravenous injection. Each Esafosfina box includes a vial of powder, a 50ml vial of solvent (sterile water for injection), and an infusion set. Therefore, the drug is also referred to as Esafosfina 5g/50ml.
Studies have shown that FdP, a key component of Esafosfina:
- Protects red blood cells from hemolysis while preventing the formation of toxic oxygen radicals in neutrophils.
- Counteracts the toxic effects of potassium on atrial contraction, thereby improving cardiac arrest conditions.
- Prevents the degradation of myocardial ATP and creatine phosphate in ischemic heart regions, protecting the liver and kidneys from ischemic damage.
- Protects against shock due to trauma or blood loss. It also promotes the resuscitation of the heart and lungs after cardiac arrest caused by hypoxia.
With these effects, Esafosfina 5g/50ml is commonly prescribed for:
- Patients with myocardial infarction, undergoing shock treatment, and those experiencing ischemia or severe ischemia in the lower limbs.
- Hypophosphatemia associated with metabolic disorders (such as metabolic diseases or severe burns requiring total parenteral nutrition). It is also used in cases of decreased 2,3-diphosphoglycerate following excessive fluid resuscitation and during extracorporeal circulation in cardiac surgery.
Contraindications for Esafosfina 5g/50ml include:
- Patients with hypersensitivity to any of the components in Esafosfina.
- Patients with hyperphosphatemia.
- Patients with renal failure.
2. Instructions for using Esafosfina
- Administration: Dissolve 5g of lyophilized Esafosfina powder in 50ml of the provided sterile water for injection to create a 10% solution. Administer by rapid intravenous infusion at a rate of 10ml/min.
- Recommended dosage: 70-160mg/kg once daily.
Note: Before infusion, inspect the solution for foreign particles; do not use Esafosfina if the solution appears cloudy or contains precipitates. The solution’s natural yellow color does not affect its efficacy.
3. Possible side effects of Esafosfina
Esafosfina is well tolerated, and no severe adverse effects have been reported. However, rapid infusion may cause pain or irritation at the injection site. If the infusion rate exceeds 10ml/min, patients may experience facial flushing, tachycardia, and finger numbness.
As with other intravenous solutions, some possible adverse reactions include fever, injection site infections, venous thrombosis or phlebitis, and extravasation. Notify a doctor immediately if any adverse symptoms occur while using Esafosfina.
4. Notes when using Esafosfina
Caution is required when using Esafosfina 5g/50ml in the following cases:
- Pregnant and breastfeeding women should consult a doctor before using Esafosfina.
- Patients with creatinine clearance <50ml/min should have their serum phosphate levels monitored.
- Esafosfina is incompatible with other intravenous solutions containing solutes at a pH of 3.5 - 5.8 or with solutions containing high calcium salt concentrations in an alkaline environment.
The above information provides essential details about Esafosfina. Before use, patients should read the instructions carefully to ensure optimal treatment outcomes. If any concerns arise, consult a doctor for appropriate guidance.
To arrange an appointment, please call HOTLINE or make your reservation directly HERE. You may also download the MyVinmec app to schedule appointments faster and manage your reservations more conveniently.
